Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012, Article ID 417673, 8 pages
http://dx.doi.org/10.1155/2012/417673
Research Article

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

1Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo, 125, 1000 Brussels, Belgium
2Medical Oncology, Galliera Hospital, Via Volta 6, 16125 Genoa, Italy

Received 4 May 2012; Accepted 1 August 2012

Academic Editor: Maryam Lustberg

Copyright © 2012 José R. Rossari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Banerjee, M. Dowsett, A. Ashworth, and L.-A. Martin, “Mechanisms of Disease: angiogenesis and the management of breast cancer,” Nature Clinical Practice Oncology, vol. 4, no. 9, pp. 536–550, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Aghajanian, N. J. Finkler, T. Rutherford et al., “OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC),” Journal of Clinical Oncology, vol. 29, supplement 18, 2011, Abstract no. LBA5007. View at Google Scholar
  3. A. Sandler, R. Gray, M. C. Perry et al., “Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer,” The New England Journal of Medicine, vol. 355, no. 24, pp. 2542–2550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Escudier, A. Pluzanska, P. Koralewski et al., “Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial,” The Lancet, vol. 370, no. 9605, pp. 2103–2111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. H. I. Hurwitz, L. Fehrenbacher, J. D. Hainsworth et al., “Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3502–3508, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Kristensen, T. Perren, W. Qian et al., “Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer,” Journal of Clinical Oncology, vol. 29, no. 18, supplement, 2011, Abstract no. LBA5006. View at Google Scholar
  8. T. N. Kreisl, L. Kim, K. Moore et al., “Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 740–745, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Allison, “Avastin's commercial march suffers setback,” Nature Biotechnology, vol. 28, no. 9, pp. 879–880, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. J. Montero and C. Vogel, “Fighting fire with fire: rekindling the bevacizumab debate,” The New England Journal of Medicine, vol. 366, no. 4, pp. 374–375, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Miller, M. Wang, J. Gralow et al., “Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer,” The New England Journal of Medicine, vol. 357, no. 26, pp. 2666–2676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. D. W. Miles, A. Chan, L. Y. Dirix et al., “Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer,” Journal of Clinical Oncology, vol. 28, no. 20, pp. 3239–3247, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. N. J. Robert, V. Dieras, J. Glaspy et al., “RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC),” Journal of Clinical Oncology, vol. 27, supplement, article 15s, Abstract no. 1005.
  14. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” BMJ, vol. 339, article b2535, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. K. Parmar, V. Torri, and L. Stewart, “Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints,” Statistics in Medicine, vol. 17, no. 24, pp. 2815–2834, 1998. View at Google Scholar
  16. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, no. 7414, pp. 557–560, 2003. View at Google Scholar · View at Scopus
  17. A. Whitehead, Meta-Analysis of Controlled Clinical Trials, Wiley, Chichester, UK, 2002.
  18. S. Hapani, D. Chu, and S. Wu, “Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis,” The Lancet Oncology, vol. 10, no. 6, pp. 559–568, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Valachis, N. P. Polyzos, N. A. Patsopoulos, V. Georgoulias, D. Mavroudis, and D. Mauri, “Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials,” Breast Cancer Research and Treatment, vol. 122, no. 1, pp. 1–7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. B. Lee, O. H. Woo, K. H. Park et al., “Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials,” Investigational New Drugs, vol. 29, no. 1, pp. 182–188, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. O'Shaughnessy et al., “A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC),” Journal of Clinical Oncology, vol. 28, article 15s, 2010, abstract no. 1005. View at Google Scholar
  22. F. Cuppone, E. Bria, V. Vaccaro et al., “Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials,” Journal of Experimental and Clinical Cancer Research, vol. 30, no. 1, article 54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. O'Shaughnessy, V. Dieras, J. Glaspy et al., “Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative Metastatic Breast Cancer (MBC),” Cancer Research, vol. 69, article 24s, 2009, abstract no. 207. View at Google Scholar
  24. T. Burzykowski, M. Buyse, M. J. Piccart-Gebhart et al., “Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 1987–1992, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. K. D. Miller, L. I. Chap, F. A. Holmes et al., “Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 792–799, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. B. I. Brufsky, V. Smirnov, S. Hurvitz et al., “RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab In combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer,” Cancer Research, vol. 69, supplement, article 24, 2009, Abstract no. 42. View at Google Scholar
  27. H. D. Bear, G. Tang, P. Rastogi et al., “Bevacizumab added to neoadjuvant chemotherapy for breast cancer,” The New England Journal of Medicine, vol. 366, no. 4, pp. 310–320, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Von Minckwitz, H. Eidtmann, M. Rezai et al., “Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer,” The New England Journal of Medicine, vol. 366, no. 4, pp. 299–309, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Cortes, V. Calvo, N. Ramírez-Merino et al., “Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis,” Annals of Oncology, vol. 23, no. 5, pp. 1130–1137, 2011. View at Google Scholar
  30. M. M. An, Z. Zou, H. Shen et al., “Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis,” European Journal of Clinical Pharmacology, vol. 66, no. 8, pp. 813–821, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu, “Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis,” JAMA, vol. 300, no. 19, pp. 2277–2285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. F. A. B. Schutz, Y. Je, G. R. Azzi, P. L. Nguyen, and T. K. Choueiri, “Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes,” Annals of Oncology, vol. 22, no. 6, pp. 1404–1412, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. T. K. Choueiri, E. L. Mayer, Y. Je et al., “Congestive heart failure risk in patients with breast cancer treated with bevacizumab,” Journal of Clinical Oncology, vol. 29, no. 6, pp. 632–638, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Ranpura, S. Hapani, and S. Wu, “Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis,” JAMA, vol. 305, no. 5, pp. 487–494, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. I. E. Smith, J. Y. Pierga, L. Biganzoli et al., “First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients,” Annals of Oncology, vol. 22, no. 3, pp. 595–602, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. H. J. Burstein, “Bevacizumab for advanced breast cancer: all tied up with a RIBBON?” Journal of Clinical Oncology, vol. 29, no. 10, pp. 1232–1235, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Dienstmann, F. Ades, K. S. Saini et al., “Benefit-risk assessment of bevacizumab in the treatment of breast cancer,” Drug Safety, vol. 35, no. 1, pp. 15–25, 2012. View at Google Scholar